Development and external validation of a clinical prediction model to estimate unfavorable graft outcome in patients with severe kidney transplant rejection eligible for treatment with alemtuzumab
Immunobiology · 2026-11 · 231 (6) · 153261
DOI: 10.1016/j.imbio.2026.153261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunobiology, 2026-11. Verfasst von Lukas K van Vugt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Transplant Institute, Rotterdam, the Netherlands; Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC,…. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Alemtuzumab is an effective therapy for severe kidney transplant rejection. Yet, not all patients benefit from this treatment, while they are at risk for its toxic effects. A prediction model could help to identify these patients and potentially guide treatment decisions. METHODS: We developed a prediction model using logistic regression and four prespecified, clinical predictor variables on a clinical dataset of two hundred patients who were treated for glucocorticoid-resistant and/or severe kidney transplant rejection with alemtuzumab. The outcome was a composite of graft loss or having a marginal graft function over the entire six months post-treatment. The model was internally validated using bootstrapping and a pilot external validation was performed with an independent validation cohort (n = 96). To make optimal use of the available data, the model was refitted to the combined datasets. Its potential for clinical utility was subsequently assessed with a decision curve analysis. RESULTS: The model included the predictors rejection subtype, timing, donor type, and dialysis dependence. It showed an optimism-corrected c-statistic and calibration slope of 0.75 and 0.81. The pilot external validation demonstrated a c-statistic of 0.71 and calibration slope of 0.86. There was a potential benefit of model-informed treatment decisions over a 'treat-all' strategy. CONCLUSION: The model showed moderate discrimination and reasonable calibration for estimating the risk of an unfavorable graft outcome after alemtuzumab treatment and warrants further external validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Erasmus MC Transplant Institute, Rotterdam, the Netherlands; Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. Elec…
- Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands; Division of Nephrology, Department of Medicine, Leiden Transplant Center, Leiden University Medical Center, Leiden University, Leiden,…
- Department of Biostatistics, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
- Leiden Transplant Center, Leiden University Medical Center, Leiden, the Netherlands.
- Erasmus MC Transplant Institute, Rotterdam, the Netherlands.
- Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Zitieren
APA
van Vugt, L. K., van den Broek, D. A. J., Miranda Afonso, P., van der Helm, D., Assis de Souza, A., de Winter, B. C. M., Reinders, M. E. J., Clahsen-van Groningen, M. C., Kers, J., de Vries, A. P. J., & Hesselink, D. A. (2026). Development and external validation of a clinical prediction model to estimate unfavorable graft outcome in patients with severe kidney transplant rejection eligible for treatment with alemtuzumab. Immunobiology, 231(6), 153261. https://doi.org/10.1016/j.imbio.2026.153261
Vancouver
van Vugt LK, van den Broek DAJ, Miranda Afonso P, van der Helm D, Assis de Souza A, de Winter BCM, et al. Development and external validation of a clinical prediction model to estimate unfavorable graft outcome in patients with severe kidney transplant rejection eligible for treatment with alemtuzumab. Immunobiology. 2026;231(6):153261. doi:10.1016/j.imbio.2026.153261
BibTeX
@article{vanVugt2026,
author = {van Vugt, Lukas K and van den Broek, Dennis A J and Miranda Afonso, Pedro and van der Helm, Danny and Assis de Souza, Alvaro and de Winter, Brenda C M and Reinders, Marlies E J and Clahsen-van Groningen, Marian C and Kers, Jesper and de Vries, Aiko P J and Hesselink, Dennis A},
title = {Development and external validation of a clinical prediction model to estimate unfavorable graft outcome in patients with severe kidney transplant rejection eligible for treatment with alemtuzumab},
journal = {Immunobiology},
year = {2026},
volume = {231},
number = {6},
pages = {153261},
doi = {10.1016/j.imbio.2026.153261}
}
EUVIMED